STING1

Stimulator of interferon genes protein · Q86WV6 · STING1 on Sugi Atlas →

53,649 patent compounds predicted against STING1, 32,630 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aceneuramic Acid (SCHEMBL1802678)	0.65	19/20
Retinal (SCHEMBL1434925)	0.62	19/20
SCHEMBL738	1.00	18/20
SCHEMBL52166	1.00	18/20
SCHEMBL1859222	0.98	18/20
Benzocaine (SCHEMBL360008)	0.75	18/20
SCHEMBL1608203	0.65	18/20
SCHEMBL1590345	0.61	18/20
SCHEMBL116836	1.00	17/20
SCHEMBL1589579	0.68	17/20
Fluorescein (SCHEMBL1434704)	0.65	17/20
Tibenelast (SCHEMBL449748)	0.54	16/20
Tibenelast (SCHEMBL635433)	0.53	16/20
SCHEMBL1106650	0.80	15/20
SCHEMBL1106664	0.80	15/20
SCHEMBL1590372	0.61	15/20
Cyclic Adenosine Monophosphate (SCHEMBL1244)	1.00	14/20
Cyclic Adenosine Monophosphate (SCHEMBL1264)	1.00	14/20
Cyclic Adenosine Monophosphate (SCHEMBL35371)	1.00	14/20
Cyclic Adenosine Monophosphate (SCHEMBL427065)	1.00	14/20

Clinical trials — most relevant to STING1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant	PHASE3	COMPLETED
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer	PHASE2	RECRUITING
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients	PHASE2	RECRUITING
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis	PHASE2	COMPLETED
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma	PHASE1	COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers	PHASE1	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)	nan	RECRUITING
Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING)	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)	nan	NOT_YET_RECRUITING
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis	nan	COMPLETED
TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus	nan	RECRUITING
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis	nan	RECRUITING
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts	nan	COMPLETED
Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile	nan	UNKNOWN
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A	nan	COMPLETED
Mechanism of DCs Dysfunction in Chronic HBV Infection	nan	UNKNOWN
Deep Phenotyping of Cutaneous Lupus Erythematosus	nan	UNKNOWN
Nasal Immune Challenge Study	nan	UNKNOWN
Gene Expression Profiling in Type 1 Diabetes	nan	COMPLETED
Tolerance in Beekeepers	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a STING1 binder may also engage these)

Protein	Name	Similarity
A0A291NUG3	—	1.000	A0A291NUG3 →
A0A291NUI4	—	0.999	A0A291NUI4 →
B8XX90	—	0.998	B8XX90 →
F1M391	—	0.997	F1M391 →
Q2KI99	—	0.997	Q2KI99 →
A0A291NUI5	—	0.995	A0A291NUI5 →
A8E5V9	—	0.993	A8E5V9 →
Q1RE32	—	0.993	Q1RE32 →
Q8BR21	—	0.993	Q8BR21 →
Q9BV19	—	0.993	Q9BV19 →
B1JV92	—	0.992	B1JV92 →
Q93TL6	—	0.992	Q93TL6 →
Q3TBT3	—	0.992	Q3TBT3 →
Q8ED56	—	0.992	Q8ED56 →
P36385	—	0.992	P36385 →
B2JHE6	—	0.992	B2JHE6 →
Q2JJA8	—	0.991	Q2JJA8 →
B5YXT5	—	0.991	B5YXT5 →
B1LLP9	—	0.991	B1LLP9 →
B7N5Q7	—	0.991	B7N5Q7 →
B2TW76	—	0.991	B2TW76 →
A7ZPA9	—	0.991	A7ZPA9 →
C4ZVI8	—	0.991	C4ZVI8 →
Q1LIP2	—	0.991	Q1LIP2 →
A6T4P4	—	0.991	A6T4P4 →
P03247	—	0.991	P03247 →
Q67167	—	0.991	Q67167 →
A0K4A1	—	0.991	A0K4A1 →
Q2PIM4	—	0.991	Q2PIM4 →
P84786	—	0.991	P84786 →